You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
和黃醫藥(00013.HK):索凡替尼就治療晚期胰腺NET藥品註冊審批完成並正待獲得認證
格隆匯 06-18 22:55

格隆匯6月18日丨和黃醫藥(00013.HK)發佈公吿,索凡替尼於2020年12月獲中國藥監局批准用於治療非胰腺NET,現由集團自有的商業化團隊以商品名蘇泰達在中國銷售。誠如招股章程所披露,公司已在中國提交索凡替尼用於治療晚期胰腺NET的第二項NDA,而其已於2020年9月獲受理,現正進行審評。2021年6月18日,公司透過中國藥監局網站得悉,索凡替尼就治療晚期胰腺NET的中國藥監局藥品註冊審批已經完成,並正待獲得認證。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account